Mutational single nucleotide polymorphism rs198389 and demethylation promoted natriuretic peptide B gene transcription in heart failure caused by dilated cardiomyopathy

Yulong Li, Mingzhi Shen, Ting Yang, Shui Yu, Jianyuan Yin, Leiming Luo, Zhao Yali, Ping Ping, Shihui FuGenes 2024 · DOI

TL;DR

This study investigates how a specific genetic variation (SNP rs198389) and DNA methylation influence the transcription of the natriuretic peptide B (NPPB) gene, a key player in heart function. The findings reveal that this SNP can enhance NPPB gene transcription, particularly when interacting with certain transcription factors, and that DNA demethylation also boosts NPPB gene expression, suggesting potential therapeutic targets for heart failure.

What Problem Does This Paper Address?

Heart failure (HF), especially when caused by dilated cardiomyopathy (DCM-HF), is a significant health concern. The B-type natriuretic peptide (BNP) system is known to be crucial in regulating cardiovascular function and its dysregulation is implicated in HF. While single nucleotide polymorphisms (SNPs) in non-coding regions, particularly promoter regions, are suspected to influence gene transcription and susceptibility to diseases like DCM-HF, the precise mechanisms are often unclear. Furthermore, DNA methylation is a known regulator of gene expression, and its role in DCM-HF development via NPPB gene transcription warrants deeper investigation. This paper aims to elucidate how a specific SNP (rs198389) in the NPPB gene promoter and DNA methylation status of the NPPB gene contribute to the transcriptional regulation of NPPB in the context of DCM-HF.

Methods

The researchers employed a multi-pronged approach:

  • Reporter Assays: They used dual-luciferase reporter assays to measure the transcriptional activity of the NPPB gene promoter. This involved cloning the promoter region (with either the wild-type or mutated rs198389 SNP) into a vector and transfecting it into human embryonic kidney 293T (HEK293T) cells. The activity was then measured, often in conjunction with the overexpression of specific transcription factors like androgen receptor (AR), glucocorticoid receptor alpha (GR-α), and retinoid X receptor alpha (RXR-α).
  • DNA Methylation Analysis: Genomic DNA was treated with sodium bisulfite to convert unmethylated cytosines to uracils, allowing for the detection of methylation patterns. They used the EpiTYPER DNA methylation analysis coupled with MassARRAY technology to quantitatively assess methylation levels at specific CpG sites within the NPPB gene promoter regions (NPPB-1 and NPPB-2).
  • Chromatin Immunoprecipitation (ChIP) Assay: This technique was used to investigate the binding of transcription factors (specifically GR-α) to the NPPB gene promoter, helping to understand how these factors interact with the DNA.
  • Quantitative PCR (qPCR) and Western Blotting: To assess the impact of demethylation on gene expression, they used decitabine (a DNA methyltransferase inhibitor) on human cardiac myocytes (HCM) cells. qPCR was used to measure NPPB mRNA levels, and Western blotting was used to quantify NPPB protein levels.
  • Sanger Sequencing: Used to identify SNP sites in the exons and introns of the NPPB gene in patient samples.
  • Enzyme-Linked Immunosorbent Assay (ELISA): Employed to measure the levels of GR-α in patient and control samples.

Datasets

The study utilized samples from two groups of participants:

  • Patients with DCM-HF: A cohort of patients diagnosed with dilated cardiomyopathy and heart failure.
  • Healthy Control Participants: A group of individuals without heart disease.

Specific participant numbers and demographic details (age, sex) are provided for different experimental cohorts within the paper. No new benchmark datasets were introduced.

Key Insights and Ideas

  • SNP rs198389 as a Promoter: The mutational form of rs198389 (C allele) in the NPPB gene promoter appears to actively promote NPPB gene transcription, contrasting with the wild-type (T allele).
  • Transcription Factor Interactions: The study highlights complex interactions between rs198389 and key transcription factors:
  • AR enhances NPPB transcription, and this effect is amplified by the mutational rs198389.
  • GR-α also promotes NPPB transcription, with a stronger effect when interacting with the wild-type rs198389.
  • RXR-α inhibits NPPB transcription, and this inhibition is more pronounced with the mutational rs198389.
  • Demethylation Boosts NPPB Expression: DNA methylation of the NPPB gene generally suppresses its transcription. Conversely, demethylation (induced by decitabine) leads to increased NPPB gene unmethylation, accelerated transcription (mRNA levels), and enhanced protein translation.
  • GR-α and DCM-HF Link: GR-α levels were found to be significantly higher in DCM-HF patients compared to healthy controls, and GR-α levels positively correlated with NT-proBNP levels, suggesting a potential role for GR-α in DCM-HF pathogenesis.

Key Results

  • Luciferase activity assays demonstrated that mutational rs198389 significantly increased NPPB gene transcription compared to the wild-type.
  • Overexpression of AR and GR-α increased NPPB promoter activity, while RXR-α decreased it, with differential effects observed depending on the rs198389 genotype.
  • ChIP assays confirmed GR-α binding to the NPPB promoter, with a preference for the wild-type rs198389.
  • CpG site CpG_5 in the NPPB gene was significantly hypo-methylated in DCM-HF patients, and its methylation levels negatively correlated with NT-proBNP levels.
  • In HCM cells, decitabine treatment dose-dependently and time-dependently increased NPPB gene unmethylation, mRNA levels, and protein levels.
  • While rs198389 (C) positively correlated with NT-proBNP levels, rs198388 (T) and rs3753581 (T) did not show significant correlations.

Limitations and Future Work

  • Limited Sample Size for SNP Analysis: While the study identified SNP sites, the percentages of mutational rs198389, rs198388, and rs3753581 did not differ significantly between DCM-HF patients and healthy controls in the initial participant cohort. However, the correlation of rs198389 with NT-proBNP levels suggests a functional relevance.
  • In Vitro vs. In Vivo: The study relies heavily on in vitro experiments (HEK293T and HCM cells). While these provide mechanistic insights, direct confirmation in human cardiac tissue or in vivo models would strengthen the findings.
  • Future Directions: The authors suggest that future population-based studies with larger sample sizes are needed to further investigate the effects of these genetic and epigenetic factors on disease severity and patient prognosis in DCM-HF. They also propose that gene editing, transcription factor enhancement, and demethylation of the NPPB gene could be potential therapeutic strategies for DCM-HF.

Summary updated

BibTeX
@inproceedings{li2024mutational,
  author = {Yulong Li and Mingzhi Shen and Ting Yang and Shui Yu and Jianyuan Yin and Leiming Luo and Zhao Yali and Ping Ping and Shihui Fu},
  title = {{Mutational single nucleotide polymorphism rs198389 and demethylation promoted natriuretic peptide B gene transcription in heart failure caused by dilated cardiomyopathy}},
  booktitle = {Genes},
  year = {2024},
  doi = {10.1016/j.gendis.2024.101345},
}
Figure